HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Sae-Hoon | - |
dc.contributor.author | Kim, Myunghwa | - |
dc.contributor.author | Lee, Kyung Wha | - |
dc.contributor.author | Kim, Sang-Heon | - |
dc.contributor.author | Kang, Hye-Ryun | - |
dc.contributor.author | Park, Heung-Woo | - |
dc.contributor.author | Jee, Young-Koo | - |
dc.date.accessioned | 2022-12-20T17:27:20Z | - |
dc.date.available | 2022-12-20T17:27:20Z | - |
dc.date.created | 2022-08-27 | - |
dc.date.issued | 2010-06 | - |
dc.identifier.issn | 1462-2416 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/174854 | - |
dc.description.abstract | Aims: The carbonic anhydrase inhibitor methazolamide infrequently causes Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). An association between these diseases and the HLA-B59 serotype has been suggested in case reports. This study examined the disease-associated B*59 allele and investigated the association of these diseases with other HLA class I alleles. Methods: We performed high-resolution HLA-A, -B and -C genotyping in five patients with methazolamide-induced SJS/TEN using a PCR-sequencing-based typing method and analyzed the association between HLA-class I alleles and occurrence of methazolamide-induced SJS/TEN. Results: B*5901 and Cw*0102 alleles were observed in all patients and A*2402 was observed in four patients. The B*5901 allele showed the strongest association with methazolamide-induced SJS/TEN (p < 0.001; odds ratio: 249.8; 95% Cl: 13.4-4813.5), followed by Cw*0102 (p = 0.004; odds ratio: 22.1; 95% Cl: 1.2-414.3), when compared with the general population as a control. The frequency of the patients carrying B*5901, Cw*0102 and A*2402 simultaneously was significantly higher than that in the general population (p < 0.001; odds ratio: 110.1; 95% Cl: 11.7-1038.6). Conclusion: A strong association was observed between HLA-B*5901 and methazolamide-induced SJS/TEN in Korean patients. HLA-B*5901 may be a useful screening marker for predicting methazolamide-induced SJS/TEN in patients of Korean and Japanese ancestry. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | FUTURE MEDICINE LTD | - |
dc.title | HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Sang-Heon | - |
dc.identifier.doi | 10.2217/PGS.10.54 | - |
dc.identifier.scopusid | 2-s2.0-77952937737 | - |
dc.identifier.wosid | 000278605900018 | - |
dc.identifier.bibliographicCitation | PHARMACOGENOMICS, v.11, no.6, pp.879 - 884 | - |
dc.relation.isPartOf | PHARMACOGENOMICS | - |
dc.citation.title | PHARMACOGENOMICS | - |
dc.citation.volume | 11 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 879 | - |
dc.citation.endPage | 884 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | HLA-B LOCUS | - |
dc.subject.keywordPlus | DNA | - |
dc.subject.keywordAuthor | carbonic anhydrase inhibitor | - |
dc.subject.keywordAuthor | human leukocyte antigen | - |
dc.subject.keywordAuthor | methazolamide | - |
dc.subject.keywordAuthor | Stevens-Johnson syndrome | - |
dc.subject.keywordAuthor | toxic epidermal necrolysis | - |
dc.identifier.url | https://www.futuremedicine.com/doi/10.2217/pgs.10.54 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.